Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Boston Scientific
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Prasugrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of ST Elevation Myocardial Infarction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 02, 2023
Lead Product(s) : Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Boston Scientific
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Abbott Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Prasugrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of ST Elevation Myocardial Infarction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Abbott Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Fujita Health University | Boston Scientific | National University of Ireland, Galway
Deal Size : Inapplicable
Deal Type : Inapplicable
Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study
Details : Prasugrel is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Acute Coronary Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 11, 2021
Lead Product(s) : Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Fujita Health University | Boston Scientific | National University of Ireland, Galway
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : U&I Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)
Details : Prasugrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Coronary Artery Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 02, 2021
Lead Product(s) : Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : U&I Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT
Details : The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of prima...
Product Name : Aggrastat
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable